Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 First-in-human Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of AMG 330 Administered as Continuous Intravenous Infusion in Subjects With Myeloid Malignancies

NCT02520427 is registered in ClinicalTrials.gov with Amgen as lead sponsor.

NCT NCT02520427
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02520427 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 First-in-human Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of AMG 330 Administered as Continuous Intravenous Infusion in Subjects With Myeloid Malignancies
Lead sponsor
Amgen
Phase
Phase 1
Overall status
Terminated
Start date
August 31, 2015
Completion date
January 9, 2022
Enrollment
95 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

minimal residual disease positive aml, myelodysplastic syndrome, relapsed/refractory aml